Published in Arch Intern Med on January 10, 2000
The impact of patients' preferences on the treatment of atrial fibrillation: observational study of patient based decision analysis. BMJ (2000) 3.93
Impact of adverse events on prescribing warfarin in patients with atrial fibrillation: matched pair analysis. BMJ (2006) 2.71
Trends in the prevalence of diagnosed atrial fibrillation, its treatment with anticoagulation and predictors of such treatment in UK primary care. Heart (2005) 2.24
Death and disability from warfarin-associated intracranial and extracranial hemorrhages. Am J Med (2007) 2.16
Practice-level variation in warfarin use among outpatients with atrial fibrillation (from the NCDR PINNACLE program). Am J Cardiol (2011) 2.06
Thromboprophylaxis of elderly patients with AF in the UK: an analysis using the General Practice Research Database (GPRD) 2000-2009. Heart (2012) 1.38
Warfarin with fluoroquinolones, sulfonamides, or azole antifungals: interactions and the risk of hospitalization for gastrointestinal bleeding. Clin Pharmacol Ther (2008) 1.30
Effects of patients' preferences on the treatment of atrial fibrillation: observational study of patient-based decision analysis. West J Med (2001) 1.30
Current issues in patient adherence and persistence: focus on anticoagulants for the treatment and prevention of thromboembolism. Patient Prefer Adherence (2010) 1.26
Impact of a patient decision aid on care among patients with nonvalvular atrial fibrillation: a cluster randomized trial. CMAJ (2005) 1.22
Physicians' perceptions of the benefits and risks of warfarin for patients with nonvalvular atrial fibrillation. CMAJ (2001) 1.13
Evaluation of a pharmacist-managed anticoagulation clinic: Improving patient care. Open Med (2009) 1.12
Should direct thrombin inhibitors replace warfarin for prophylaxis of thromboembolism in canadians with atrial fibrillation? Can J Hosp Pharm (2012) 1.07
Predictors of warfarin use in atrial fibrillation in the United States: a systematic review and meta-analysis. BMC Fam Pract (2012) 1.07
Patients' perspectives on taking warfarin: qualitative study in family practice. BMC Fam Pract (2004) 1.03
Application of a decision support tool for anticoagulation in patients with non-valvular atrial fibrillation. J Gen Intern Med (2008) 1.01
Cost-effectiveness of apixaban compared with warfarin for stroke prevention in atrial fibrillation. PLoS One (2012) 0.99
Impact of age, CYP2C9 genotype and concomitant medication on the rate of rise for prothrombin time during the first 30 days of warfarin therapy. Clin Med Res (2005) 0.99
Identifying the risks of anticoagulation in patients with substance abuse. J Gen Intern Med (2013) 0.94
Percutaneous left atrial appendage closure for stroke prevention in atrial fibrillation. Neth Heart J (2012) 0.94
National utilization patterns of warfarin use in older patients with atrial fibrillation: a population-based study of Medicare Part D beneficiaries. Ann Pharmacother (2013) 0.92
Atrial fibrillation in a primary care practice: prevalence and management. BMC Fam Pract (2002) 0.91
Values and preferences in oral anticoagulation in patients with atrial fibrillation, physicians' and patients' perspectives: protocol for a two-phase study. BMC Health Serv Res (2008) 0.91
Is warfarin really underused in patients with atrial fibrillation? J Gen Intern Med (2001) 0.89
Stroke prevention in atrial fibrillation in older adults: existing knowledge gaps and areas for innovation: a summary of an American Federation for Aging research seminar. J Am Geriatr Soc (2013) 0.88
Do physician outcome judgments and judgment biases contribute to inappropriate use of treatments? Study protocol. Implement Sci (2007) 0.87
Mechanical antithrombotic intervention by LAA occlusion in atrial fibrillation. Nat Rev Cardiol (2013) 0.86
A randomized trial to assess the impact of an antithrombotic decision aid in patients with nonvalvular atrial fibrillation: the DAAFI trial protocol [ISRCTN14429643]. BMC Cardiovasc Disord (2004) 0.86
Stroke prevention in atrial fibrillation: concepts and controversies. Curr Cardiol Rev (2012) 0.86
TRial of an Educational intervention on patients' knowledge of Atrial fibrillation and anticoagulant therapy, INR control, and outcome of Treatment with warfarin (TREAT). BMC Cardiovasc Disord (2010) 0.84
Stroke risk in AF: do AF patterns matter? Eur Heart J (2010) 0.84
Erratum: utilization of anticoagulation therapy in medicare patients with nonvalvular atrial fibrillation. Am Health Drug Benefits (2012) 0.84
Implementing hospital guidelines improves warfarin use in non-valvular atrial fibrillation: a before-after study. BMC Public Health (2007) 0.84
Clinical epidemiology of atrial fibrillation and related cerebrovascular events in the United States. Neurologist (2008) 0.83
Association between CHADS₂risk factors and anticoagulation-related bleeding: a systematic literature review. Mayo Clin Proc (2011) 0.83
Use of antithrombotic medications among elderly ischemic stroke patients. Circ Cardiovasc Qual Outcomes (2010) 0.83
Novel Oral Anticoagulant Use Among Patients With Atrial Fibrillation Hospitalized With Ischemic Stroke or Transient Ischemic Attack. Circ Cardiovasc Qual Outcomes (2015) 0.83
Management of atrial fibrillation. Vasc Health Risk Manag (2007) 0.83
Multinational development of a questionnaire assessing patient satisfaction with anticoagulant treatment: the 'Perception of Anticoagulant Treatment Questionnaire' (PACT-Q). Health Qual Life Outcomes (2009) 0.83
Advancement in antithrombotics for stroke prevention in atrial fibrillation. J Interv Card Electrophysiol (2008) 0.83
Impact of stated barriers on proposed warfarin prescription for atrial fibrillation: a survey of Canadian physicians. Thromb J (2014) 0.82
Geriatric assessment and anticoagulation in elderly patients with chronic atrial fibrillation. Arch Intern Med (2000) 0.82
Oral heparin: status review. Thromb J (2006) 0.82
Stroke Prevention in Atrial Fibrillation: Where are We Now? Clin Med Insights Cardiol (2012) 0.82
Improving anticoagulation in atrial fibrillation: observational study in three primary care trusts. Br J Gen Pract (2014) 0.80
Should a patient with primary intracerebral haemorrhage receive antiplatelet or anticoagulant therapy? BMJ (2005) 0.80
Warfarin therapy for atrial fibrillation: the patient's preference is important. Arch Intern Med (2000) 0.80
Contraindications to anticoagulation therapy and eligibility for novel anticoagulants in older patients with atrial fibrillation. Cardiovasc Ther (2015) 0.79
Underuse of oral anticoagulants in patients with nonvalvular atrial fibrillation in Italy. Intern Emerg Med (2007) 0.79
Cardioembolic stroke in atrial fibrillation-rationale for preventive closure of the left atrial appendage. Korean Circ J (2009) 0.79
Developing an Atrial Fibrillation Guideline Support Tool (AFGuST) for shared decision making. Curr Med Res Opin (2015) 0.79
Non-vitamin K antagonist oral anticoagulation usage according to age among patients with atrial fibrillation: Temporal trends 2011-2015 in Denmark. Sci Rep (2016) 0.79
Improving outpatient warfarin use for hospitalized patients with atrial fibrillation. Pharm Pract (Granada) (2008) 0.78
Exploring barriers to optimal anticoagulation for atrial fibrillation: interviews with clinicians. J Multidiscip Healthc (2012) 0.78
Anticoagulant use for prevention of stroke in a commercial population with atrial fibrillation. Am Health Drug Benefits (2012) 0.78
Pharmacotherapy for atrial fibrillation in elderly hospitalized patients with comorbid congestive heart failure in australia: A retrospective study. Curr Ther Res Clin Exp (2008) 0.78
Oral anticoagulation in elderly patients as secondary prevention of cardioembolic strokes. Int Arch Med (2010) 0.78
Outcome Predictors in First-Ever Ischemic Stroke Patients: A Population-Based Study. Int Sch Res Notices (2014) 0.77
Ximelagatran: direct thrombin inhibitor. Vasc Health Risk Manag (2006) 0.76
The use of antithrombotics in patients presenting with stroke and atrial fibrillation. Ther Clin Risk Manag (2007) 0.76
How well does the target INR level maintain in warfarin-treated patients with non-valvular atrial fibrillation? Yonsei Med J (2009) 0.76
Left atrial appendage closure in patients with atrial fibrillation in whom warfarin is contra-indicated: initial South African experience. Cardiovasc J Afr (2013) 0.76
Breaks in continuity of care and the rural senior transferred for medical care under regionalisation. Int J Integr Care (2003) 0.76
Measures of vitamin K antagonist control reported in atrial fibrillation and venous thromboembolism studies: a systematic review. BMJ Open (2014) 0.76
Predictors of gastrointestinal bleeding among patients with atrial fibrillation after initiating dabigatran therapy. Pharmacotherapy (2015) 0.76
Could some geriatric characteristics hinder the prescription of anticoagulants in atrial fibrillation in the elderly? J Aging Res (2014) 0.76
Association between atrial fibrillation, anticoagulation, risk of cerebrovascular events and multimorbidity in general practice: a registry-based study. BMC Cardiovasc Disord (2016) 0.75
The New 3D Printed Left Atrial Appendage Closure with a Novel Holdfast Device: A Pre-Clinical Feasibility Animal Study. PLoS One (2016) 0.75
Patients' and physicians' perceptions and attitudes about oral anticoagulation and atrial fibrillation: a qualitative systematic review. BMC Fam Pract (2017) 0.75
Summary of scientific evidence. Occas Pap R Coll Gen Pract (2002) 0.75
Use of Chronic Medications Among Patients with Non-Valvular Atrial Fibrillation. Drugs Real World Outcomes (2016) 0.75
A role for pharmacists in community-based post-discharge warfarin management: protocol for the 'the role of community pharmacy in post hospital management of patients initiated on warfarin' study. BMC Health Serv Res (2011) 0.75
Management of patients with atrial fibrillation: specific considerations for the old age. Cardiol Res Pract (2011) 0.75
Prevalence of atrial fibrillation in Thai elderly. J Geriatr Cardiol (2016) 0.75
Improving stroke prevention therapy for patients with atrial fibrillation in primary care: protocol for a pragmatic, cluster-randomized trial. Implement Sci (2016) 0.75
Direct thrombin inhibitors: novel antithrombotics on the horizon in the thromboprophylactic management of atrial fibrillation. Postgrad Med J (2005) 0.75
Preventing stroke in atrial fibrillation patients - clinical utility of oral anticoagulants. J Blood Med (2012) 0.75
A standardized bleeding risk score aligns anticoagulation choices with current evidence. Crit Pathw Cardiol (2014) 0.75
A non-experimental study of oral anticoagulation therapy initiation before and after national patient safety goals. BMJ Open (2014) 0.75
Five years of keeping a watch on the left atrial appendage-how has the WATCHMAN fared? J Thorac Dis (2016) 0.75
Influence of Competing Risks on Estimating the Expected Benefit of Warfarin in Individuals with Atrial Fibrillation Not Currently Taking Anticoagulants: The Anticoagulation and Risk Factors in Atrial Fibrillation Study. J Am Geriatr Soc (2016) 0.75
Contemporary approaches to managing atrial fibrillation: A survey of Australian general practitioners. Australas Med J (2015) 0.75
Non-Vitamin K Antagonist Oral Anticoagulants: New Choices for Patient Management in Atrial Fibrillation. Am J Cardiovasc Drugs (2015) 0.75
Using an Atrial Fibrillation Decision Support Tool for Thromboprophylaxis in Atrial Fibrillation: Effect of Sex and Age. J Am Geriatr Soc (2016) 0.75
Safety and efficacy of apixaban in the treatment of atrial fibrillation. Clin Med Insights Cardiol (2012) 0.75
The use of practitioner education and a warfarin monitoring service to improve anticoagulation practices. Arch Intern Med (2000) 0.75
Warfarin usage among elderly atrial fibrillation patients with traumatic injury, an analysis of United States Medicare fee-for-service enrollees. J Clin Pharmacol (2014) 0.75
Stroke Prevention in Atrial Fibrillation. J Atr Fibrillation (2010) 0.75
Impact of Rural Residence on Warfarin Use and Clinical Events in Patients with Non-Valvular Atrial Fibrillation: A Canadian Population Based Study. PLoS One (2015) 0.75
Left Atrial Appendage: Physiology, Pathology, and Role as a Therapeutic Target. Biomed Res Int (2015) 0.75
Cardiac embolism after implantable cardiac defibrillator shock in non-anticoagulated atrial fibrillation: The role of left atrial appendage occlusion. World J Cardiol (2014) 0.75
Anticoagulation for non-valvular atrial aibrillation - towards a new beginning with ximelagatran. Curr Control Trials Cardiovasc Med (2004) 0.75
[Patient selection for the implantation of a left atrial appendage occluder in primary and secondary prevention of cardioembolic stroke in atrial fibrillation]. Herzschrittmacherther Elektrophysiol (2013) 0.75
The impact of surgical left atrial appendage amputation/ligation on stroke prevention in patients undergoing off-pump coronary artery bypass grafting. Heart Vessels (2016) 0.75
Do population studies confirm the benefit of oral anticoagulation in atrial fibrillation demonstrated in clinical trials? J Interv Card Electrophysiol (2004) 0.75
Differences in risk factors, atherosclerosis, and cardiovascular disease between ethnic groups in Canada: the Study of Health Assessment and Risk in Ethnic groups (SHARE) Lancet (2000) 8.01
Randomised trials of secondary prevention programmes in coronary heart disease: systematic review. BMJ (2001) 5.63
A systematic review of randomized trials of disease management programs in heart failure. Am J Med (2001) 5.38
Dancing with the porcupine: rules for governing the university-industry relationship. CMAJ (2001) 3.85
Progression of kidney dysfunction in the community-dwelling elderly. Kidney Int (2006) 3.64
Physician interpretations and textbook definitions of blinding terminology in randomized controlled trials. JAMA (2001) 3.32
What is the quality of drug therapy clinical practice guidelines in Canada? CMAJ (2001) 3.15
Assessing the quality of randomized trials: reliability of the Jadad scale. Control Clin Trials (1999) 2.99
Comparative safety and effectiveness of sitagliptin in patients with type 2 diabetes: retrospective population based cohort study. BMJ (2013) 2.92
Recurrent cerebral ischemia in medically treated patent foramen ovale: a meta-analysis. Neurology (2009) 2.70
Missed opportunities for prevention in general internal medicine. CMAJ (1999) 2.68
Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection. Circulation (1994) 2.61
Evidence-based medicine: a commentary on common criticisms. CMAJ (2000) 2.48
Extended out-of-hospital low-molecular-weight heparin prophylaxis against deep venous thrombosis in patients after elective hip arthroplasty: a systematic review. Ann Intern Med (2001) 2.37
Contemporary practice patterns in the management of newly diagnosed hypertension. CMAJ (1997) 2.23
Practice-based research: lessons from community pharmacist participants. Pharmacotherapy (2001) 2.23
Physicians' attitudes towards prevention: importance of intervention-specific barriers and physicians' health habits. Fam Pract (2000) 2.13
Acute precipitants of congestive heart failure exacerbations. Arch Intern Med (2001) 2.11
Use of statins and the subsequent development of deep vein thrombosis. Arch Intern Med (2001) 1.82
Insights into the contemporary epidemiology and outpatient management of congestive heart failure. Am Heart J (1999) 1.75
Ethnic differences in the relationships between obesity and glucose-metabolic abnormalities: a cross-sectional population-based study. Int J Obes (Lond) (2005) 1.72
A novel process for updating recommendations for managing hypertension: rationale and methods. Can J Cardiol (2000) 1.71
The impact of leaving against medical advice on hospital resource utilization. J Gen Intern Med (2000) 1.64
Derivation and validation of a clinical index for prediction of rapid progression of kidney dysfunction. QJM (2007) 1.59
Poor long-term survival after coronary angiography in patients with renal insufficiency. Am J Kidney Dis (2001) 1.55
Validation of three myocardial jeopardy scores in a population-based cardiac catheterization cohort. Am Heart J (2001) 1.55
The Southern Alberta Renal Program database: a prototype for patient management and research initiatives. Clin Invest Med (2001) 1.52
Selection of patients for randomized controlled trials: implications of wide or narrow eligibility criteria. Stat Med (1990) 1.50
Early uptake of research findings after fast-track publication. Lancet (2000) 1.49
Dealing with missing data in observational health care outcome analyses. J Clin Epidemiol (2000) 1.49
Comparison of risk and patterns of practice in patients older and younger than 70 years with acute myocardial infarction in a two-year period (1987-1989) Am J Cardiol (1991) 1.48
Use of chelation therapy after coronary angiography. Am J Med (2001) 1.46
Critical impact of patient knowledge and bone density testing on starting osteoporosis treatment after fragility fracture: secondary analyses from two controlled trials. Osteoporos Int (2014) 1.45
Physician estimates of perioperative cardiac risk in patients undergoing noncardiac surgery. Arch Intern Med (1999) 1.45
Simultaneous carotid endarterectomy and coronary artery bypass surgery in Canada. Neurology (2005) 1.41
Use of beta-blockers for uncomplicated hypertension in the elderly: a cause for concern. J Hum Hypertens (2007) 1.40
Comparative response of male and female patients with coronary artery disease to exercise rehabilitation. Eur Heart J (1984) 1.38
Differences in risk factors, atherosclerosis and cardiovascular disease between ethnic groups in Canada: the study of health assessment and risk in ethnic groups (SHARE). Indian Heart J (2001) 1.33
Behaviour of canine pulmonary vagal afferent receptors during sustained acute pulmonary venous pressure elevation. J Physiol (1987) 1.32
The impact of alcohol-related diagnoses on pneumonia outcomes. Arch Intern Med (1997) 1.27
Characteristics of patients with pneumonia who are discharged from hospitals against medical advice. Am J Med (1999) 1.26
Reviewing the reviewers: the quality of reporting in three secondary journals. CMAJ (2001) 1.25
The Study of Health Assessment and Risk in Ethnic groups (SHARE): rationale and design. The SHARE Investigators. Can J Cardiol (1998) 1.22
Quality of life in patients treated with hemodialysis or peritoneal dialysis: what are the important determinants? Clin Nephrol (2003) 1.21
Primary stenting versus balloon angioplasty in occluded coronary arteries: the Total Occlusion Study of Canada (TOSCA). Circulation (1999) 1.21
Community pharmacist-initiated screening program for osteoporosis: randomized controlled trial. Osteoporos Int (2009) 1.20
Abnormal cardiac enzyme responses after strenuous exercise: alternative diagnostic aids. Br Med J (Clin Res Ed) (1982) 1.19
Prevalence, incidence, primary care burden and medical treatment of angina in Scotland: age, sex and socioeconomic disparities: a population-based study. Heart (2006) 1.19
The management of congestive heart failure. Postgrad Med J (1997) 1.16
Mortality risk and patterns of practice in 2,070 patients with acute myocardial infarction, 1987-92. Relative importance of age, sex, and medical therapy. Chest (1994) 1.15
Physicians' perceptions of the benefits and risks of warfarin for patients with nonvalvular atrial fibrillation. CMAJ (2001) 1.13
National survey of the prevalence, incidence, primary care burden, and treatment of heart failure in Scotland. Heart (2004) 1.11
Adequacy of anticoagulation in patients with atrial fibrillation coming to a hospital. Pharmacotherapy (2000) 1.10
Cholesterol risk management: a systematic examination of the gap from evidence to practice. Pharmacotherapy (2001) 1.10
A survey of clinician attitudes and management practices in hypertension. J Hum Hypertens (1997) 1.04
The changing clinical profile of coronary artery bypass graft patients, 1970-89. Can J Cardiol (1994) 1.04
Underutilisation of ACE inhibitors in patients with congestive heart failure. Drugs (2001) 1.03
Effects of exercise training in patients with congestive heart failure: a critical review. J Am Coll Cardiol (1995) 1.02
Predictors of improvement in left ventricular function after percutaneous revascularization of occluded coronary arteries: a report from the Total Occlusion Study of Canada (TOSCA). Am Heart J (2001) 1.02
Cardiac rehabilitation referral and attendance: not one and the same. Rehabil Nurs (1999) 1.01
Geographic variation in the rate of carotid endarterectomy in Canada. Stroke (2001) 1.01
Timing of initial administration of low-molecular-weight heparin prophylaxis against deep vein thrombosis in patients following elective hip arthroplasty: a systematic review. Arch Intern Med (2001) 1.00
Interferon-alpha/beta inhibits IgE-dependent histamine release from rat mast cells. Immunology (1989) 0.99
Stimulation of rapidly adapting pulmonary stretch receptors by pulmonary lymphatic obstruction in dogs. Can J Physiol Pharmacol (1988) 0.98
Effect of pulmonary venous congestion on respiratory rate in dogs. J Physiol (1989) 0.98
Reflex tracheal contraction during pulmonary venous congestion in the dog. J Physiol (1988) 0.98
Predicting and explaining cardiac rehabilitation attendance. Can J Cardiol (2001) 0.97
Clinical assessment of the reliability of the examination (CARE). ACP J Club (2000) 0.96
Hospital cost of complications associated with coronary artery bypass graft surgery. Am J Cardiol (1997) 0.96
Association between obesity and health-related quality of life in patients with coronary artery disease. Int J Obes (Lond) (2010) 0.95
Nurse case-manager vs multifaceted intervention to improve quality of osteoporosis care after wrist fracture: randomized controlled pilot study. Osteoporos Int (2010) 0.94
Using focus groups to identify barriers to drug use in patients with congestive heart failure. Pharmacotherapy (2000) 0.94
Audit of the consultation process on general internal medicine services. Qual Saf Health Care (2009) 0.93
Effects of tissue-type plasminogen activator and anisoylated plasminogen streptokinase activator complex on mortality in acute myocardial infarction. Circulation (1990) 0.93
Cardiac rehabilitation: the forgotten intervention. Can J Cardiol (1999) 0.93
Study of Cardiovascular Risk Intervention by Pharmacists (SCRIP): a randomized trial design of the effect of a community pharmacist intervention program on serum cholesterol risk. Ann Pharmacother (1999) 0.93
The treatment and prevention of coronary heart disease in Canada: do older patients receive efficacious therapies? The Clinical Quality Improvement Network (CQIN) Investigators. J Am Geriatr Soc (1999) 0.93
Reliability and validity of measures of cardiac output during incremental to maximal aerobic exercise. Part II: Novel techniques and new advances. Sports Med (1999) 0.93
The 2000 Canadian recommendations for the management of hypertension: part two--diagnosis and assessment of people with high blood pressure. Can J Cardiol (2001) 0.92
Cardiac output measured by impedance cardiography during maximal exercise tests. Cardiovasc Res (1985) 0.91
Clinical assessment of clonidine in the treatment of new-onset rapid atrial fibrillation: a prospective, randomized clinical trial. Am Heart J (2001) 0.91
Weight management experiences of overweight and obese Canadian adults: findings from a national survey. Chronic Dis Inj Can (2012) 0.91
Psychosocial components of cardiac recovery and rehabilitation attendance. Heart (2001) 0.90
Reliability and validity of measures of cardiac output during incremental to maximal aerobic exercise. Part I: Conventional techniques. Sports Med (1999) 0.90
A case study of hospital closure and centralization of coronary revascularization procedures. CMAJ (2001) 0.89
Physicians' recommendations for patients who undergo noncardiac surgery. Clin Invest Med (2000) 0.89
Use of nonprescription medications by patients with congestive heart failure. Ann Pharmacother (1999) 0.88